Little is known about the value of the nutritional risk screening 2002 scale in nasopharyngeal carcinoma (NPC). We conducted a large-scale study to address this issue. We employed a big-data intelligence database platform at our 
| INTRODUCTION
The nasopharygeal epithelial carcinoma (NPC) has distinct epidemiology and treatment regimens from other head and neck cancers. The age-standardized incidence of NPC is 20-50 per 100 000 males in endemic areas such as southern China 1,2 but only 0.5 per 100 000 in predominantly white populations. 2 Radical surgery is not an option due to anatomical constraints; radiotherapy is the primary and only curative treatment for non-metastatic disease, which is highly radiosensitive, while radiotherapy combined with chemotherapy is standard for advanced disease. [3] [4] [5] [6] [7] As the oral mucosa is unavoidably included in the radiation target volume, severe oral mucositis frequently disrupts oral function and integrity, 8 and can cause severe pain and reduce nutritional intake, resulting in significant weight loss. Weight loss and poor nutritional status are associated with more severe toxicities during chemotherapy 9 and radiotherapy 10 and a poorer response to infection, 11 and adversely affect prognosis in head and neck cancers. 11 In addition, numerous studies have demonstrated that poor nutrition or weight loss are associated with poorer survival outcomes in NPC. [12] [13] [14] [15] Therefore, nutrition and weight loss are major concerns for both clinicians and patients with NPC. However, previous studies have only assessed a single index (i.e. a prognostic nutritional index or weight), without considering disease or baseline characteristics, and could not adequately identify patients at risk of poor nutrition and weight loss. Thus, a tool that enables early identification of the highrisk subpopulation for delivery of nutritional interventions needs to be developed urgently.
The nutritional risk screening 2002 (NRS2002) scale, developed by the European Society for Clinical Nutrition and Metabolism (ESPEN), 16 has been validated for identifying patients at risk who may benefit from nutritional intervention in various cancers, 17, 18 including head and neck cancers. 19 However, the NRS2002 has never been applied in NPC. Given the urgent clinical need, we conducted a retrospective study using a large-scale, big-data intelligence platform to assess the value of the NRS2002 for identifying individuals at high risk of poor nutrition in NPC among patients treated with intensity-modulated radiotherapy (IMRT).
| MATERIALS AND METHODS

| Participants
We employed a big-data intelligence database, which has been described in detail previously 20 
| Staging workup
All patients underwent head and neck physical examinations, direct fibre-optic nasopharyngoscopy, MRI scan of skull to sternoclavicular joint, chest radiography or computed tomography (CT), abdominal sonography and whole-body bone scans. PET-CT was performed to evaluate metastasis, if clinically indicated. All patients received routine dental evaluations before radiotherapy.
Local tumor extension (T category) and lymph node metastasis (N category) of patients were re-staged according to the 8th edition of the International Union against Cancer/American Joint Committee on Cancer (UICC/AJCC) tumor-node-metastasis system.
Two radiologists (L.Z.L and L.T) employed at our hospital with over 10 years' experience separately reviewed all imaging data to minimize heterogeneity in restaging; disagreements were resolved by consensus.
| NRS2002 assessment
Nutritional risk during radiotherapy was assessed according to the NRS2002 scale (Table S1 ), which takes into account severity of disease (mild, moderate and severe) and impaired nutritional status (mild, moderate and severe), with an adjustment for age of ≥70 years. Two doctors (H.P and B.B.C) from the radiation oncology and medical oncology departments independently reviewed patients' medical history, weekly height and weight, weekly blood and biochemical profiles and food intake to determine the NRS2002 score for each patient. For the sections on "severity of disease" and "age," patients were scored before radiotherapy according to the individual medical history and age records. For 
| Clinical treatment and nutritional intervention
All patients received radical IMRT using the simultaneous integrated boost technique at our center. 21, 22 Nasogastric feeding was not possible, as the patients could not accept a nasogastric tube. 3 | RESULTS
| Follow-up and endpoints
T A B L E 1 (Continued) Characteristics Low-risk (NRS2002 < 3) N = 482 High-risk (NRS2002 ≥ 3) N = 2750 P-value Number (%) Number (%)
| Patient selection
Searches of the big-data platform using the keyword "nasopharyn- The associations between NRS2002 score and severity of disease, impaired nutritional status and age are presented in Table S2 . Obviously, most patients (2750/3232; 85.1%) suffered nutritional impairment; therefore, patients were subdivided into low-risk (NRS2002 < 3, n = 482) and high-risk (NRS ≥ 3, n = 2750) groups using established NRS2002 score cut-off values. The baseline characteristics of these groups are compared in Table 1 . The high-risk group had significantly more patients with advanced T category (P < .001), N category (P < .001) and overall stage (P < .001). Consequently, the high-risk group were more likely to receive more intensive treatment such as IC (P < .001) or concurrent cisplatin (P < .001). All other factors were well-balanced between the low-risk and high-risk groups.
F I G U R E 1 Kaplan-Meier DFS (A), OS (B), DMFS (C) and LRRFS (D) curves for the 476 pairs of patients stratified as low risk (NRS2002 <3)
and high risk (NRS2002 ≥ 3) using the NRS2002 scale. DFS, disease-free survival; DMFS, distant metastasis-free survival; LRRFS, locoregional relapse-free survival; NRS, nutritional risk screening; OS, overall survival
| Factors associated with NRS2002 score
Multivariate logistic regression was used to identify factors associated with NRS2002 score in NPC ( 3.3 | Survival differences for patients with NRS2002 score <3 or ≥3
In total, 476 pairs were selected by PSM and the baseline information is summarized in Table S3 . By last visit, the median follow-up duration for the 476 matched pairs was 59.53 (8.03-
84.43) months. The estimated 5-year DFS, OS, DMFS) and LRRFS
rates for the matched low-risk and high-risk groups were 85.3%
vs 82.5% (P = .274), 91.4% vs 89.0% (P = .221), 91.8% vs 89.0%
(P = .123) and 93.3% vs 91.5% (P = .344, Figure 1 ), respectively.
When entered into multivariate analysis, the NRS2002 score was an independent prognostic factor only for DMFS (HR, 1.673; 95% CI, 1.092-2.562; P = .018), but not DFS, OS or LRRFS (Table 3) .
| Survival analysis after regrouping
We conducted univariate survival analysis between different NRS2002 score groups (Figure 2) . Surprisingly, patients with an NRS2002 score of 3 achieved significantly better DFS, OS and DMFS than those with NRS2002 scores of 4 and 5, and similar outcomes to patients with NRS2002 scores of 1 and 2. Therefore, we reclassified patients with NRS2002 scores of 3 as low-risk (NRS2002 ≤ 3, n = 1436). Subsequently, 1168 pairs were selected from the original cohort; the baseline characteristics of these groups are shown in Table S4 .
In comparison with the high-risk (NRS2002 Table S5 ).
| Proposal of a revised NRS2002 scale
Previous studies 24, 25 focusing on elderly patients applied an age cutoff value of 65 years. Moreover, Du et al 12 found that weight loss of ≥10% was associated with significantly poorer survival outcomes.
Therefore, we proposed a revised NRS2002 scale for NPC (Table S6 ). According to the revised NRS2002 scale, 517 (16.0%), 898 (27.8%), 1504 (46.5%), 307 (9.5%) and 6 (0.2%) patients had scores of 1, 2, 3, 4 and 5, respectively (Table S7) 
| DISCUSSION
Our current study verified the prognostic value of the NRS2002 scale in NPC and found the survival outcomes of patients with CI, confidence interval; DFS, disease-free survival; DMFS, distant metastasis-free survival; HR, hazard ratio; LRRFS, locoregional relapse-free survival; NRS, nutritional risk screening; OS, overall survival LDH, lactate dehydrogenase.
a P-values were calculated using an adjusted Cox proportional-hazards model with backward elimination and the following parameters: age (>45 y vs ≤45 y), gender (female vs male), smoking (yes vs no), drinking (yes vs no), family history of cancer (yes vs no), LDH (>245 vs ≤245 U/ L), T category (T3-4 vs T1-2), N category (N2-3 or N0-1), overall stage (III-IV vs I-II), induction chemotherapy (yes vs no), cumulative cisplatin dose (≥200 vs <200 mg/m 2 ) and NRS2002 score (≥3 vs <3).
NRS2002 scores <3 and ≥3 were comparable. Further analysis revealed that patients with NRS2002 scores ≤3 achieved significantly better outcomes than patients with NRS2002 scores >3, indicating the cut-off values of the conventional NRS2002 scale may not be directly relevant to NPC. Thus, we proposed and validated a revised NRS2002 scale for NPC with more powerful risk stratification ability than the original or regrouping NRS2002 scale. We also identified the factors associated with the NRS2002 score in NPC. To the best of our knowledge, this is the first study to apply the NRS2002 scale to assess nutritional risk for individual patients with NPC.
Before conducting our study, we searched the literature and identified 3 main nutritional risk assessment scales: NRS2002 scale, 18, 19, 26, 27 patient-generated subjective global assessment (PG-SGA) scale [28] [29] [30] [31] and mini nutritional assessment (MNA) scale.
32-34
These 3 scales were proven effective for nutritional assessment for patients with malignancies. However, some items in the PG-SGA and MNA scales were not routinely assessed and recorded before or during treatment in our center. Consequently, nutritional assessment using these 2 scales was not available. Therefore, we adopted the NRS2002 scale.
It should be noted that we did not consider NRS2002 during IC, as compliance to IC is satisfactory and few patients suffer nutritional impairment during this process. In fact, only 92/1654 (5.6%) patients who received IC experienced nutritional impairment (Table S8) . Moreover, patients usually returned home after receiving IC, making it more difficult to assess nutritional status. Hence, we did not evaluate the NRS2002 score during IC. As age is one of the criteria in the NRS2002 scale, we did not restrict age when recruiting participants; therefore, some patients younger than 18 years old were included. According to the guidelines of our hospital, a disease severity score ≥2 was a strong contraindication for radiotherapy. Therefore, all patients in this study had a disease severity score of 1.
We found advanced tumor stage, IC and a higher CCD during radiotherapy were associated with a significantly higher NRS2002 score, which is similar to previous findings. 12 Obviously, patients with advanced stage disease received more intensive chemotherapy regimens and, therefore, were more likely to suffer more severe nutritional impairment. However, insufficient chemotherapy may also adversely affect prognosis. As both low and extreme treatment intensities correlate with poorer survival outcomes, it is important to deliver the optimal treatment intensity to obtain the best prognosis. With regard to IC, more efficacious and less toxic regimens should be considered, such as gemcitabine plus cisplatin. 35, 36 In addition, the number of cycles of IC should be optimized; 2 cycles may be sufficient. 37 For concurrent chemotherapy, an overdose of cisplatin should be 42, 43 Given that nutrition has a significant impact on prognosis, it is essential to identify patients at high risk of nutritional impairment and to deliver nutritional intervention as early as possible. Based on our finding that patients with an NRS2002 score of 3 achieved excellent outcomes, similar to patients with lower scores, it is reasonable to infer that the original NRS2002 scale may not provide adequate nutritional risk stratification in NPC. Therefore, based on previous studies, 12, 24, 25 we made some modifications to the age and weight loss criteria to establish a revised NRS2002
scale. ROC curve analysis revealed that the revised NRS2002 scale achieved the best power in risk stratification than the original NRS2002 and regrouping scales for all end-points. Thus, the revised NRS2002 scale represents a simple, powerful nutritional risk screening tool for patients with NPC that could help to inform clinical decision-making.
Compared to previous studies of nutritional status in NPC, [12] [13] [14] [15] this is the first application of the NRS2002 scale to consider age and severity of disease as well as nutritional status. The proposed revised NRS2002 scale provides more comprehensive understanding of patient and disease status, and may, therefore, have more significant clinical value than the individual indexes (weight loss or prognostic nutritional index) investigated in previous studies. [12] [13] [14] [15] Moreover, this was the largest sample size investigated to date, which confers greater statistical power to detect significant differences. Given the unbalanced distribution of some factors between different NRS2002 score groups, we used the PSM method to match these factors and reduce potential bias. The limitations of F I G U R E 3 Kaplan-Meier DFS (A), OS (B), DMFS (C) and LRRFS (D) curves for the 1168 pairs of patients stratified as low risk (NRS2002 ≤ 3) and high risk (NRS2002 > 3) using the NRS2002 scale. DFS, disease-free survival; DMFS, distant metastasis-free survival; LRRFS, locoregional relapse-free survival; NRS, nutritional risk screening; OS, overall survival this study should also be noted. Importantly, data from a single center was retrospectively assessed. However, we applied PSM and multivariate analysis to balance various factors and address the potential limitations of divergent confounders. Moreover, the effect of IC was not explored in detail and requires further study.
The relationship between radiotherapy interruption and NRS2002 score was not evaluated because many patients did not have this data.
In summary, tumor stage and chemotherapy intensity are significantly associated with NRS2002 score in NPC, and patients with a NRS2002 score >3 have significantly poorer survival outcomes than those with a NRS score ≤3 in the IMRT era. Moreover, we proposed and validated a revised NRS2002 scale that better enables identification of patients at high risk of nutritional impairment. The revised NRS2002 scale needs to be validated in randomized clinical trials.
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